Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — H1 2015 Earnings Presentation
21 slides from Novo Nordisk A/s Class B's earnings presentation, Aug 7, 2015
Slide 1: Investor presentation First six months of 2015
Slide 1 Investor presentation First six months of 2015 London, 7 August 2015 Mexico City – part of Cities Changing Diabetes
Slide 2: Agenda
Investor presentation First six months of 2015 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
Slide 3: Forward-looking statements
Investor presentation First six months of 2015 Slide 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2014 and Form 20-F, both filed with the SEC in February
Slide 4: Highlights – first six months of 2015
Investor presentation First six months of 2015 Slide 4 Highlights – first six months of 2015 Sales development • Sales increased by 25% in Danish kroner and 9% in local currencies • North America and International Operations grew by 35% and 26% in Danish kroner, respectively • Victoza® increased by
Slide 5: North America is the main contributor to growth
Investor presentation First six months of 2015 Slide 5 North America is the main contributor to growth Sales as reported – First six months of 2015 Growth analysis – First six months of 2015 Japan & Korea Local currencies Growth Share of growth Region China +10% North America 10% 56% +25% 5% 10% Eur
Slide 6: Decelerated growth in China reflects timing of shipments, lower market growth and intensified competition
Investor presentation First six months of 2015 Slide 6 Decelerated growth in China reflects timing of shipments, lower market growth and intensified competition Decelerating sales growth Key factors impacting sales growth in the first six months of 2015 in the first six months of 2015 Sales as repor
Slide 7: Growth is driven by Victoza and modern insulin
Investor presentation First six months of 2015 Slide 7 Growth is driven by Victoza® and modern insulin Sales as reported – First six months of 2015 Growth analysis – First six months of 2015 Other Local currencies Growth Share of growth Norditropin® +29% New-generation insulin N/A 10% +30% 3% 3% Mod
Slide 8: Victoza maintains leadership in the faster growing US GLP-1 market
Investor presentation First six months of 2015 Slide 8 Victoza® maintains leadership in the faster growing US GLP-1 market US GLP-1 market development US GLP-1 market shares MAT GLP-1 Growth rate Total TRx MAT volume GLP-1 TRx Victoza® exenatide TRx (000) growth rate market share albiglutide dulaglu
Slide 9: Novo Nordisk's modern insulins perform well within their respective segments in the US
Investor presentation First six months of 2015 Slide 9 Novo Nordisk’s modern insulins perform well within their respective segments in the US Levemir® NovoLog® NovoLog® Mix TRx volume MS NBRx volume MS TRx volume MS NBRx volume MS TRx volume MS NBRx volume MS TRx segment volume MU TRx segment volume
Slide 10: Roll-out of degludec portfolio is progressing
Investor presentation First six months of 2015 Slide 10 Roll-out of degludec portfolio is progressing Tresiba® value share of basal insulin segment Key launch observations in selected countries Switzerland India United Kingdom • Tresiba® launched in 30 countries Japan Sweden Germany • Tresiba® has s
Slide 11: Encouraging early prescription development for Saxenda
Investor presentation First six months of 2015 Slide 11 Encouraging early prescription development for Saxenda® Prescription volume uptake of anti-obesity medications recently launched in the US Key launch observations TRx Naltrexone HCI & bupropion HCI Lorcaserin • Encouraging initial Saxenda® upta
Slide 12: Semaglutide shows superior HbA1c reduction and weight loss compared with placebo in SUSTAIN 1 trial
Investor presentation First six months of 2015 Slide 12 Semaglutide shows superior HbA1c reduction and weight loss compared with placebo in SUSTAIN® 1 trial SUSTAIN® 1 trial design Headline results 0.5 mg 1.0 mg Placebo semaglutide semaglutide Semaglutide 0.5 mg Change in HbA1c 388 drug- -1.5%* -1.6
Slide 13: Liraglutide as adjunct to insulin therapy leads to greater HbA1c reduction and weight loss in ADJUNCT TWO trial
Investor presentation First six months of 2015 Slide 13 Liraglutide as adjunct to insulin therapy leads to greater HbA1c reduction and weight loss in ADJUNCT TWO trial ADJUNCT TWO trial design1 Headline results • Greater improvement in HbA1c between 0.2% and 0.3% for people with type 1 diabetes comp
Slide 14: Saxenda shows sustained weight loss and reduced risk of type 2 diabetes vs placebo after three years
Investor presentation First six months of 2015 Slide 14 Saxenda® shows sustained weight loss and reduced risk of type 2 diabetes vs placebo after three years in SCALE® trial Sustained weight loss with Saxenda® in SCALE® obesity and prediabetes trial Saxenda® effect on emerging type 2 diabetes Saxend
Slide 15: Key development milestones
Investor presentation First six months of 2015 Slide 15 Key development milestones DEVOTE trial now expected to be completed mid-2016 compared to previously in the second half of 2016 First phase 2a proof-of-principle trial with oral insulin analogue OI338GT (NN1953) initiated in June 2015 First pha
Slide 16: Significant news flow from late-stage diabetes and obesity pipeline
Investor presentation First six months of 2015 Slide 16 Significant news flow from late-stage diabetes and obesity pipeline Results available Project Past 6 months Past 3 months Within 3 months In ~3-6 months In ~6-9 months Oral GLP-1 Phase 2 √ Faster-acting ONSET® 1 √ insulin aspart ONSET® 2 √ Saxe
Slide 17: Financial results – first six months of 2015
Investor presentation First six months of 2015 Slide 17 Financial results – first six months of 2015 DKK million H1 2015 H1 2014 Change Sales 52,259 41,972 25% Gross profit 44,526 34,835 28% Gross margin 85.2% 83.0% Sales and distribution costs 13,322 10,645 25% Percentage of sales 25.5% 25.4% Resea
Slide 18: Appreciation of key currencies against the Danish krone drive significant positive currency impact in 2015
Investor presentation First six months of 2015 Slide 18 Appreciation of key currencies against the Danish krone drive significant positive currency impact in 2015 USD/DKK CNY/DKK JPY/DKK GBP/DKK CAD/DKK 135 Index (1 Jan 2014 = 100) Hedged 2014 2015 Spot Impact of a Hedging 130 Currencies average ave
Slide 19: Financial outlook for 2015
Investor presentation First six months of 2015 Slide 19 Financial outlook for 2015 Expectations Previous expectations 6 August 2015 30 April 2015 Sales growth - local currencies 7-9% 7-9% Sales growth - reported Around 14 percentage points higher Around 16 percentage points higher Operating profit g
Slide 20: Closing remarks
Investor presentation First six months of 2015 Slide 20 Closing remarks Solid market performance Promising pipeline >≥10% annual diabetes care market growth driven •> • The only company with a full portfolio of novel by diabetes prevalence insulin products • 28% market share in diabetes care and sol
Slide 21: Investor contact information
Investor presentation First six months of 2015 Slide 21 Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New York